177Lu-DOTA-ibandronic acid (SKB107) / Sichuan Kelun Pharma - LARVOL DELTA

SKB107: (PRNewswire) - "A RDC drug jointly developed by the Company and the Affiliated Hospital of Southwest Medical University...targeting bone metastases in solid tumors. In March 2025, an IND application for SKB107 was approved by the NMPA and the Phase 1 study is ongoing."

Trial status • Solid Tumor

Kelun-Biotech’s Radionuclide-Drug Conjugate (RDC) SKB107 Receives NMPA Approval For The Treatment of Bone Metastases in Solid Tumors (PRNewswire) - "Sichuan Kelun-Biotech Biopharmaceutical...announced that the Company has received a clinical trial notice approving the investigational new drug application for a radionuclide-drug conjugate (RDC) drug SKB107 (formerly TBM-001) from the Center for Drug Evaluation of the National Medical Products Administration. SKB107 is the first company RDC drug clinical project....It utilizes a small molecule as the targeting ligand, combined with a suitable conjugation technology, chelator, and therapeutic radionuclide, and is intended to be used for treatment of bone metastases in solid tumors"

New trial • Solid Tumor